CME Stock CME Group (CME, $269.53) was a top weekly gainer, with a +5.26% jump
at Tickeron.com
Loading...
CME Group (CME, $269.53) was one of the top gainers this week, climbing to $269.53 per share. A.I.dvisor analyzed 15 stocks in the Financial Publishing/Services Industry over the last week and discovered that of them (4) trended up while of them (5) trended down.
CME's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for CME turned positive on June 12, 2026. Looking at past instances where CME's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CME's RSI Indicator exited the oversold zone, of 14 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 57 cases where CME's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CME advanced for three days, in of 339 cases, the price rose further within the following month. The odds of a continued upward trend are .
CME may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 261 cases where CME Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on May 26, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CME as a result. In of 104 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
CME moved below its 50-day moving average on May 20, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CME declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 76, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.659) is normal, around the industry mean (5.208). P/E Ratio (22.997) is within average values for comparable stocks, (24.881). CME's Projected Growth (PEG Ratio) (4.725) is very high in comparison to the industry average of (2.026). CME has a moderately high Dividend Yield (0.042) as compared to the industry average of (0.020). CME's P/S Ratio (14.409) is slightly higher than the industry average of (7.989).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CME’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.